Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D2KOX5
|
|||
| Drug Name |
BMS-986301
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
Bristol-Myers Squibb
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Stimulator of interferon genes protein (TMEM173) | Target Info | Agonist | [2] |
| KEGG Pathway | NOD-like receptor signaling pathway | |||
| RIG-I-like receptor signaling pathway | ||||
| Cytosolic DNA-sensing pathway | ||||
| Human cytomegalovirus infection | ||||
| Herpes simplex virus 1 infection | ||||
| Human immunodeficiency virus 1 infection | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03956680) An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers. U.S. National Institutes of Health. | |||
| REF 2 | Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy. J Clin Med. 2020 Oct 16;9(10):3323. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.